No statically significant differences in ESR, CRP, TNF levels, and albumin were observed pre- and post-switch from the infliximab originator to the biosimilar. Ross Maltz, MD“Studies in adults with inflammatory bowel disease (IBD) have demonstrated that a one-time switch from the originator to a biosimilar has not resulted in loss of response, increased side effects, or antibody development,” wrote Ross Maltz, MD, associate professor and pediatric gastroenterologist in the Department of Pediatrics at the Ohio State Wexner Medical Center. NON-MEDICAL SWITCHING FROM INFLIXIMAB TO A BIOSIMILAR IN PEDIATRICS AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE